SCHEMBL4950433

SCHEMBL4950433

NC(=O)c1cc(C(F)(F)F)ccc1C[CH]C(=O)Nc1cnc2ccccc2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 2/20 0.50
CNR2 P34972 2/20 0.50
TRPV1 Q8NER1 4/20 0.47
KDR P35968 3/20 0.45
MTOR P42345 1/20 0.45
RAB9A P51151 5/20 0.44
NPC1 O15118 4/20 0.44
KDM4E B2RXH2 3/20 0.44
POLB P06746 2/20 0.44
LMNA P02545 1/20 0.44
TSHR P16473 1/20 0.44
HSD17B10 Q99714 1/20 0.44
MITF O75030 1/20 0.44
XBP1 P17861 1/20 0.44
PAX8 Q06710 1/20 0.44
KLF5 Q13887 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
HDAC4 P56524 1/20 0.43
ALPL P05186 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4949892 0.91 CNR1 (0.49) CNR1CNR2TRPV1KDRMTOR
SCHEMBL4945840 0.90 CNR2 (0.39) CNR1CNR2TRPV1MTOR
SCHEMBL5184303 0.88 RAB9A (0.47) CNR1CNR2TRPV1KDRRAB9A
SCHEMBL4949376 0.88 NPC1 (0.46) TRPV1RAB9ANPC1POLBTSHR
SCHEMBL5183675 0.86 NPSR1 (0.51) KDRRAB9ANPC1KDM4EPOLB
SCHEMBL4952020 0.79 CNR1 (0.41) CNR1CNR2TRPV1KDRMTOR
SCHEMBL5185017 0.78 RAB9A (0.46) CNR1CNR2TRPV1KDRRAB9A
SCHEMBL4947375 0.77 NPSR1 (0.46) KDRRAB9ANPC1KDM4EPOLB
SCHEMBL5185045 0.77 NPC1 (0.49) RAB9ANPC1POLBLMNATSHR
SCHEMBL5184813 0.76 NPSR1 (0.49) TRPV1KDRRAB9ANPC1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080076741-A1 ENHANCEMENT OF TIGECYCLINE POTENCY USING EFFLUX PUMP INHIBITORS REMPEX PHARMACEUTICALS, INC. 2008-03-27 US disclosed
EP-1758920-A1 BACTERIAL EFFLUX PUMP INHIBITORS AND METHODS OF TREATING BACTERIAL INFECTIONS MPEX PHARMACEUTICALS, INC. (US) 2007-03-07 EP disclosed
US-20060003944-A1 Bacterial efflux pump inhibitors and methods of treating bacterial infections REMPEX PHARMACEUTICALS, INC. 2006-01-05 US disclosed
WO-2005113579-A1 BACTERIAL EFFLUX PUMP INHIBITORS AND METHODS OF TREATING BACTERIAL INFECTIONS MPEX PHARMACEUTICALS, INC. (US) 2005-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076741-A1 ENHANCEMENT OF TIGECYCLINE POTENCY USING EFFLUX PUMP INHIBITORS ABCB1, ABCB11, SLC47A2 CNR1 4488/4885CNR2 4711/4885TRPV1 3093/4885
US-20060003944-A1 Bacterial efflux pump inhibitors and methods of treating bacterial infections ABCB11, ABCB1, ABCC1 CNR1 3772/4885CNR2 4069/4885TRPV1 2189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.